Dossier assessment
Sarilumab (rheumatoid arthritis) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Sarilumab (rheumatoid arthritis) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Sarilumab (rheumatoid arthritis) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Moderate to severe active rheumatoid arthritis
Hint of an added benefit for patients for whom treatment with biologic disease-modifying antirheumatic drugs (bDMARD) is indicated for the first time and who do not tolerate MTX. Other patient groups: added benefit not proven
Project details
- Project no.
- A17-39
- Commission
- Commission awarded on 15.08.2017 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Muscles, bones and joints
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Sarilumab (polyarticular juvenile idiopathic arthritis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Sarilumab (polymyalgia rheumatica) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed